Rapport Therapeutics Says $815.4 Million In Cash Funds It Through 2029 After Bipolar Mania Win

The drug developer's third-quarter net loss grew to $40.2 million as spending on RAP-219 rose, but October financing lifted its cash position.

Share
Rapport Therapeutics Says $815.4 Million In Cash Funds It Through 2029 After Bipolar Mania Win

Rapport Therapeutics, a clinical-stage company developing small molecule medicines for neurological and psychiatric disorders, said Wednesday it has estimated cash of $815.4 million and expects that to fund operations through the end of 2029. The figure follows an October financing, while its third-quarter net loss widened to $40.2 million, or $0.84 per share, from $26.9 million, or $0.71, a year earlier.

Bigger bills for RAP-219

Research and development spending rose to $34.3 million from $22.3 million a year earlier, the company said in an 8-K. It tied the increase to costs of the Phase 3 focal onset seizure program, the finish of the bipolar mania Phase 2 trial and wider pipeline work.

Selling, general and administrative expense was $9.8 million, versus $7.7 million, on growth in headcount and pay. Interest income was $3.9 million against $3.1 million. Rapport ended September with $395.0 million in cash, cash equivalents and short-term investments, down from $436.1 million at June 30.

A $410.7 million financing

In October, Rapport completed a public offering of stock at $21.00 per share, with pre-funded warrants at $20.999 for some investors, plus an offering of 2.25% convertible senior notes due 2032 and a concurrent private placement of stock at the offering price. Net proceeds were about $410.7 million.

In November the company also sold roughly $10 million of stock under its at-the-market program at $25.05 per share. The $815.4 million estimate is unaudited and covers cash, cash equivalents and short-term investments: the September 30 balance plus about $420.7 million from the October and November sales.

Bipolar mania data and the road ahead

On October 20, Rapport reported that RAP-219 met the main goal of a randomized, placebo-controlled Phase 2 trial in 253 adults with bipolar I disorder in an acute manic episode. Patients showed a 3.1-point improvement over placebo on the Young Mania Rating Scale at Week 3 (p=0.045). All treatment-emergent adverse events were mild or moderate, with no serious ones, and 3.2% of RAP-219 patients stopped treatment because of one, versus 0.8% on placebo.

CEO Abraham N. Ceesay called the results "transformational for Rapport." The company says RAP-219 now has proof-of-concept in epilepsy and bipolar mania.

Rapport plans an FDA meeting on bipolar mania trial design in the first quarter of 2027, with two Phase 3 trials expected to start in the second half of 2027. A Phase 3 trial in primary generalized tonic-clonic seizures is expected to begin in the first half of 2027.

Initial data from the open-label long-term epilepsy safety trial are due in the fourth quarter of 2026.

Sources

More on Rapport Therapeutics

All Rapport Therapeutics (RAPP) coverage →